Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JinBi Granules is a Traditional Chinese Medicine (TCM) formulation developed by Longhua Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is designed for the treatment of chronic musculoskeletal conditions, specifically cervical spondylosis, lumbar disc herniation, and knee osteoarthritis. In TCM theory, these conditions are often categorized under "Bi syndrome," characterized by the obstruction of qi and blood in the meridians. The formulation is typically administered as "free fried granules" (mianjian keli), which are concentrated herbal extracts that do not require traditional decoction. Clinical trials have focused on evaluating its efficacy and safety in elderly patients suffering from degenerative bone and joint diseases, utilizing a "different diseases with the same therapy" research approach.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JinBi Granules.